<DOC>
	<DOCNO>NCT01156051</DOCNO>
	<brief_summary>This study seek determine , use special sleep test ( polysomnography actigraphy ) guanfacine extend release able improve nighttime sleep child ADHD - associate insomnia improve daytime ADHD symptom . Male female child diagnose suspect ADHD sleep problem ( difficulty fall asleep , difficulty stay asleep , less expected hour sleep ) recruit . After obtain informed consent assent ( appropriate ) discontinuation exclude medication , child evaluation sleep evaluation confirm ADHD diagnosis . Children successfully pass screen enrol double-blind , placebo-controlled , randomized investigation 50 % participant receive guanfacine extend release 50 % participant receive match placebo . Using flexible-dose optimization design base ADHD symptom improvement medication tolerability , dose adjust 1 4 mg course four week . At end medication adjustment ( week 4 5 ) , ADHD questionnaires , sleep questionnaire , sleep test repeat analyzed . The medication wean course follow 3-10 day .</brief_summary>
	<brief_title>Effect Guanfacine Extended-Release Attention Deficit Hyperactivity Disorder ( ADHD ) -Associated Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>1 . Subject must male female , age 6 12 year ADHD . 2 . Subject must ( ) take methylphenidate , amphetamine , atomoxetine treatment ADHD parent subject concern inadequate efficacy intolerable side effect , ( b ) free medication use treat ADHD least 30 day time initial sleep study . 3 . Subject must repeat difficulty sleep initiation persistence despite attempt adequate sleep hygiene . 4 . Subject must able swallow tablet . 1 . Subject parent/LAR unable unwilling discontinue present medication use treat ADHD . 2 . Subject body mass index &lt; 5th percentile age , use Centers Disease Control standard report 2000 . 3 . Subject body weight &gt; 176 pound . 4 . Subject diagnosis Autism Autism Spectrum Disorder . 5 . Subject serious psychiatric diagnosis . 6 . Subject medical condition may require treatment unapproved medication , may cause safety concern , may confound outcome result 7 . Subject excessive caffeine intake ( great 2.5 mg/kg/d ) . 8 . Subject prior problem clonidine guanfacine .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>ADHD</keyword>
	<keyword>ADD</keyword>
	<keyword>sleep disturbance</keyword>
</DOC>